He talks about KRAS degraders, claudin 18.2, AAV gene therapy, and more. Plus, how Astellas thinks about the coming patent expiry of Xtandi.

He describes the launch, physician and patient feedback, and responds in his own words to short seller criticism.

He discusses the rationale behind acquiring a DGAT-2 and GLP-1, and how a non-pharma sized company has been able to succeed with a new drug launch.

He discusses the $145M 4Q number that was announced at JPM, and the real world feedback the company has been receiving from physicians and patients. Plus, how the thinks about Insmed now that it is a $35B market cap company.

She discusses the profile of the drug, which is currently in a phase 3 study, and the data Bluejay had previously presented on it. Plus, her advice for other entrepreneurs who might be fielding bids.

She discusses the launch and financial guidance for next year, and highlights obesity and Huntington's programs.

Biotech veteran and Summit Chairman Bob Duggan and Summit's Chief Strategy and Business Officer Dave Gancarz discuss the filing, and discuss trying to stay out front and on top in this emerging new class of medicines.

She describes the HOPE-3 data, the regulatory filing, which has already been initiated in part, and what she believes this treatment means for DMD patients.

He discusses programs covering dry eye, ocular pain, AMD, geographic atrophy, and more. Plus, how he using Bausch + Lomb's expertise in the eye and investing in biotech technologies of the future.

He discusses regulatory feedback the company has received that might allow it to earn an accelerated approval in antitrypsin deficiency. Plus, filing for sickle cell later this year, and how he thinks about new targets.

He discusses the theme of his annual letter that was published today, "Choosing Science," and why it is important that our country continues to invest in basic research. Plus, his take on the M&A environment in biotech.

He discusses Biohaven, Xenon, Biogen, and Sarepta.

Founder and CEO Marshall Fordyce talks about the data that supported the application and describes how atacicept’s novel mechanism holds the potential to transform the treatment of the autoimmune disease. He says the company is getting ready to launch, with a PDUFA date set for July.

He discusses the company's degrader programs, TYK2/JAK1, using myostatin for obesity, and a Kv7 epilepsy program that will have key data this year.

He discusses the company's accomplishments to date, and highlights learnings about the mechanism and important data in 2026 in the maintenance setting for UC and Crohn's later this year.

While describing his early life in Washington and formative years at the University of Chicago that led to the founding of ARCH, he shares his thoughts on leadership, risk taking, changes he thinks are need to keep the United States competitive in life sciences, and his belief in AI's promise to transform our industry. Chapters Intro and early life – 0:44 Risk taking and leaders – 7:54 University of Chicago – 26:12 ARCH – 36:25 China – 48:07 Brain Health – 58:16 Project Prom

His widely read report shows the data behind what venture deals got done last year, who are the venture investors that have been most active in deploying capital, the fundraising and IPO environment, and which technologies and indications are seeing the most investor interest. DOWNLOAD THE FREE REPORT #sponsored

He discusses BridgeBio, Cytokinetics, Vaxcyte, Biogen, and Arcus Biosciences Chapters BridgeBio - 1:08 Cytokinetics - 12:14 Vaxcyte - 17:40 Biogen - 23:43 Arcus Biosciences - 26:48

He discusses the recently approved Wegovy pill, and compares and contrasts it to other oral programs from Lilly, Structure, and Corbus. Plus, how is the amylin space looking compared to GLP-1s, and a preview of Viking's 2026. Chapters Wegovy in a pill - 1:04 Lilly’s pill orforglipron - 9:14 Structure’s pill aleniglipron - 13:13 Lilly’s retatrutide - 16:33 Amylins (Zealand and others) - 19:47 Corbus’ CB1 inverse agonist – 24:53 Viking - 28:02